

PRESS RELEASE

Cordlife Awarded "Most Transparent Company" Award at SIAS' 14th Investors' Choice Awards

SINGAPORE, 8 November 2013 - **Cordlife Group Limited** ("Cordlife", and together with its subsidiaries, the "Group"), a multi-product healthcare company catering to the mother and child segment, announced today that it was presented the "Most Transparent Company Award" in the Retail & Household Goods Category and Mainboard Small Caps Category at this evening's SIAS Investors' Choice Awards. Last year, Cordlife was a runner-up for the same award in the New Issues Category, having been newly-listed on the Mainboard of the Singapore Exchange ("SGX-ST") on March 29, 2012.

The Investors' Choice Awards, now in its 14th year, honour companies and individuals who have achieved excellence in advancing corporate governance practices, including promoting greater corporate transparency.

"It is indeed a great honour and privilege to be recognised for our efforts to make our operations clear and easily understandable for our stakeholders and investors. We are proud of two consecutive years of award wins. I will like to take this opportunity to thank SIAS and its partners for organising the awards and all those who nominated Cordlife for this honour.

This demonstrates the confidence that the financial and investing community has in Cordlife, with respect to our commitment to build trust in the marketplace and engage in open communications with all stakeholders. Going forward, we will continue to participate in pro-active, open communications with all our stakeholders."

Mr. Jeremy Yee, Executive Director and Chief Executive Officer of Cordlife

The awards were presented at a dinner event held tonight at Resorts World Convention Centre.

- The End -

The initial public offering of Cordlife's shares was sponsored by PrimePartners Corporate Finance Pte. Ltd., who assumes no responsibility for the contents of this release.



ABOUT CORDLIFE GROUP LIMITED (Bloomberg stock code: CLGL)

Incorporated in May 2001, Cordlife Group Limited ("Cordlife", and together with its subsidiaries, the "Group"), is a multi-product healthcare company catering to the mother and child segment and a leading cord blood and tissue banking services provider. Amongst the first private cord blood banks in Asia, Cordlife has established a dominant market leader position in Singapore¹. Today, it has the larger market share of the only two private cord blood banks. Cordlife completed the acquisition of the cord blood and cord tissue banking businesses and assets in India, the Philippines and Indonesia from Australia-listed Life Corporation Limited (formerly known as Cordlife Limited) in June 2013.

Cordlife collects, processes, tests, cryopreserves and stores stem cells from the umbilical cord blood of the child at birth, allowing customers to preserve their child's cord blood stem cells for treatment later in his or her life if their child so requires. In March 2011, the Group launched umbilical cord tissue banking service in Hong Kong, offering an additional service that allows customers to collect and store their child's umbilical cord tissue, which is a rich source of mesenchymal and epithelial stem cells and may potentially help repair the body in different ways. In May 2013, Cordlife Technologies Pte. Ltd., a wholly-owned subsidiary of Cordlife Group Limited, launched umbilical cord tissue banking service in Singapore. The storage and banking of umbilical cord tissue services provided in Singapore is currently not licensed by the Ministry of Health, Singapore. This service is provided on a research/clinical trial basis.

In addition, Cordlife, through its collaborative relationships or arrangements with major private hospitals and clinics such as Thomson Medical and Parkway East Hospital, has continued to increase public awareness of its cord blood banking services in Singapore. Overseas, the Group has a 10% direct stake in China Cord Blood Corporation – a top operator in China holding majority shares in the Beijing, Guangdong and Zhejiang Cord Blood Banks, and an approximately 20% share in Shandong Cord Blood Bank.

Cordlife has been accredited since 2005 by AABB (formerly known as the American Association of Blood Banks), an association involved in the field of transfusion medicine and cellular therapies. The Group is one of the first private cord blood banks in Singapore and amongst the first in Hong Kong to have released cord blood units for transplants and other therapeutic use. In Singapore, Cordlife was the first private cord blood bank to release cord blood units for the treatment of cerebral palsy.

Cordlife's track record has won the Group many accolades and awards, including: Best Medical Service Award 2010 by Capital CEO Supreme Brand Awards; Top Pregnant/Baby Products Award 2011 by Pregnancy Magazine; Outstanding Financial Strength Cord Blood Bank 2012 by Quamnet Outstanding Enterprise Awards; Most Popular Brand Award 2010 – The Most Popular Cord Blood Bank by TVB Weekly; and U-Choice Lifestyle Brand Award 2010 by Metroinfo FM99.7; Baby & Kid Brands Awards year 2013, "My Favourite Cord Blood Bank" by Hong Kong Economic Times; and Baby Kingdom Top 10 Family Brand Award 2012². In October 2012, Cordlife was awarded the prestigious SIAS Investors' Choice Awards as runner-up in the "Most Transparent Company Award 2012"

¹ Source : Deloitte & Touche Financial Advisory Services Limited report, 10 April 2013

² Awarded to Cordlife (Hong Kong) Limited



New Issues Category. In August 2013, we were presented with Merit Award for the Singapore Corporate Awards 2013, "Best Investor Relations Award". In November 2013, Cordlife was named the "Most Transparent Company Award 2013" in the Retail & Household Goods Category and Mainboard Small Caps Category at the 14th SIAS Investors' Choice Awards.

ISSUED ON BEHALF OF	
BY	: Financial PR Pte Ltd
	4 Robinson Road #04-01
	The House of Eden
	Singapore 048543
CONTACT	: Mr Gabriel Tan / Mr Kamal Samuel
OFFICE	: 6438-2990
EMAIL	: gabriel@financialpr.com.sg /
	kamal@financialpr.com.sg